Loading...
XASX
OCC
Market cap164mUSD
Dec 05, Last price  
1.01AUD
1D
0.00%
1Q
-10.62%
Jan 2017
165.79%
IPO
172.97%
Name

Orthocell Ltd

Chart & Performance

D1W1MN
XASX:OCC chart
P/E
P/S
32.72
EPS
Div Yield, %
Shrs. gr., 5y
5.48%
Rev. gr., 5y
60.03%
Revenues
8m
+42.05%
524,281691,405790,430666,499529,818619,179945,657719,5231,017,9621,531,7184,243,0695,315,3757,550,681
Net income
-9m
L+19.30%
-1,323,330-2,182,185-3,742,715-3,784,864-4,177,416-5,757,114-5,852,214-6,151,029-9,037,025-9,106,585-6,248,181-7,180,959-8,566,640
CFO
-9m
L+33.48%
-290,572-1,753,026-2,767,613-3,321,118-3,555,380-4,644,252-4,180,466-5,256,871-4,633,330-6,261,45614,592,580-6,505,126-8,682,928

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental application; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
IPO date
Aug 12, 2014
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT